药学前沿大讲堂第141讲-Synthesis and Antibacterial Activity of Thiazomycin Analogs (Thiazomycin结构类似物的合成及抗菌活性研究)

Synthesis and Antibacterial Activity of Thiazomycin Analogs (Thiazomycin结构类似物的合成及抗菌活性研究)

发布人:高级管理员
主题
Synthesis and Antibacterial Activity of Thiazomycin Analogs (Thiazomycin结构类似物的合成及抗菌活性研究)
活动时间
-
活动地址
中山大学东校区bm11222宝马娱乐网站 125讲学厅
主讲人
刘堃博士(Kun Liu, Ph.D.)
主持人
鄢明 教授

bm11222宝马娱乐网站十周年院庆系列活动­

药学前沿大讲堂第141

 

  目:Synthesis and Antibacterial Activity of Thiazomycin Analogs Thiazomycin结构类似物的合成及抗菌活性研究)

报告人:刘堃博士(Kun Liu, Ph.D.

Director and Asia Lead External Medicinal Chemistry Merck Sharp & Dohme

主持人:鄢明 教授  bm11222宝马娱乐网站

  间:20130109日(周三) 上午1030

  点:中山大学东校区bm11222宝马娱乐网站 125讲学厅

 

报告人简介:

 

Kun Liu graduated from Fudan University in 1988 with a BS in Chemistry and completed his Ph.D. in 1995 at University of Rochester with Professor Andrew Kende. He then pursued a post-doctoral fellowship at Harvard University under Professor E. J. Corey before joining Merck in July 1997 as a Senior Research Chemist in the medicinal chemistry department at Rahway site.  He moved to Merck External Basic Research in May of 2008 as a Chemistry Collaboration Lead, responsible for the successful execution of drug discovery programs through external collaborations with biotechnology companies, contract research organizations, and academic institutions around the globe. In September of 2011, Kun was appointed Asia Lead of DPS and relocated to Shanghai.

Kun has drug discovery experience in multiple therapeutic areas, including diabetes, obesity, cardiovascular disease, oncology, infectious disease, and immunology, and has successfully advanced drug candidates to clinical development.  Dr. Liu served as an executive council member of Sino-American Pharmaceuticals Professional Association (SAPA). He has published over 30 papers in peer reviewed journals and holds more than 30 patents.

 

欢迎广大师生踊跃参加!